Literature DB >> 7559215

Fiber type-specific effects of clenbuterol and exercise training on insulin-resistant muscle.

C E Torgan1, G J Etgen, H Y Kang, J L Ivy.   

Abstract

The interrelationships among glucose uptake, GLUT-4 protein, and citrate synthase activity in insulin-resistant skeletal muscle were investigated. Female obese (fa/fa) Zucker rats were randomly assigned to treadmill training, ingestion of the selective beta 2-adrenergic agonist clenbuterol, or sedentary control groups. After 7-8 wk of treatment, hindlimbs were perfused to determine maximal insulin-stimulated (10 mU/ml) 2-[3H]deoxy-D-glucose (2-DG) uptake. Exercise training significantly enhanced 2-DG uptake and GLUT-4 protein in red gastrocnemius and plantaris. Alternatively, 2-DG uptake was not altered in soleus after exercise training despite a 52% increase in GLUT-4 protein. The increases in GLUT-4 protein in red gastrocnemius, plantaris, and soleus of the trained rats were accompanied by increases in citrate synthase activity. In contrast to exercise training, clenbuterol administration decreased citrate synthase activity in red and white gastrocnemius, yet had no effect on GLUT-4 protein levels or maximal insulin-stimulated 2-DG uptake. Clenbuterol treatment did, however, increase citrate synthase activity and GLUT-4 protein in soleus. These findings indicate that total GLUT-4 protein largely determines the maximal rate of insulin-stimulated glucose uptake in fast-twitch muscle, whereas in slow-twitch muscle it does not. In addition, the results demonstrate that coordination of proteins governing glucose uptake and disposal may be disrupted in a fiber type-specific manner. Overall, the findings raise important questions as to whether regulation of proteins governing glucose uptake and disposal differs significantly among fiber types.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559215     DOI: 10.1152/jappl.1995.79.1.163

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

Review 1.  The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

Authors:  E Davis; R Loiacono; R J Summers
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

2.  Clustering of GLUT4, TUG, and RUVBL2 protein levels correlate with myosin heavy chain isoform pattern in skeletal muscles, but AS160 and TBC1D1 levels do not.

Authors:  Carlos M Castorena; James G Mackrell; Jonathan S Bogan; Makoto Kanzaki; Gregory D Cartee
Journal:  J Appl Physiol (1985)       Date:  2011-07-28

3.  Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses.

Authors:  David R Plant; Charles F Kearns; Kenneth H McKeever; Gordon S Lynch
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

4.  Chronic β2 -adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men.

Authors:  Morten Hostrup; Johan Onslev; Glenn A Jacobson; Richard Wilson; Jens Bangsbo
Journal:  J Physiol       Date:  2017-11-12       Impact factor: 5.182

Review 5.  The effect of muscle-damaging exercise on blood and skeletal muscle oxidative stress: magnitude and time-course considerations.

Authors:  Michalis G Nikolaidis; Athanasios Z Jamurtas; Vassilis Paschalis; Ioannis G Fatouros; Yiannis Koutedakis; Dimitris Kouretas
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

6.  Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle.

Authors:  Jatin G Burniston; Lynn McLean; Robert J Beynon; David F Goldspink
Journal:  Muscle Nerve       Date:  2007-02       Impact factor: 3.217

7.  Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle.

Authors:  Pascal Sirvent; Aymerick Douillard; Olivier Galbes; Christelle Ramonatxo; Guillaume Py; Robin Candau; Alain Lacampagne
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.